Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

In this observational, population-based study, variations in ESA administration impacted response in transfusion-dependent MDS patients, with higher response rates with early administration and use of darbepoetin, and low response likelihood in non-responders beyond 16 weeks of therapy.